BDBM621137 3,5-difluoro-N-((3S,4S)-4- fluoropiperidin-3-yl)-6-(7- isopropoxyimidazo[1,2- a]pyridin-3-yl)pyridin-2- amine::US20230303563, Compound 208

SMILES CC(C)Oc1ccn2c(cnc2c1)-c1nc(N[C@H]2CNCC[C@@H]2F)c(F)cc1F

InChI Key InChIKey=HCHLTTBJHNWMPS-UHFFFAOYSA-N

Data  3 IC50  11 Kd

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 14 hits for monomerid = 621137   

TargetInterleukin-1 receptor-associated kinase 1(Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621137(3,5-difluoro-N-((3S,4S)-4- fluoropiperidin-3-yl)-6...)
Affinity DataIC50: 8nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621137(3,5-difluoro-N-((3S,4S)-4- fluoropiperidin-3-yl)-6...)
Affinity DataIC50: 0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621137(3,5-difluoro-N-((3S,4S)-4- fluoropiperidin-3-yl)-6...)
Affinity DataIC50: 0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621137(3,5-difluoro-N-((3S,4S)-4- fluoropiperidin-3-yl)-6...)
Affinity DataKd:  0.220nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835H](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621137(3,5-difluoro-N-((3S,4S)-4- fluoropiperidin-3-yl)-6...)
Affinity DataKd:  0.310nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621137(3,5-difluoro-N-((3S,4S)-4- fluoropiperidin-3-yl)-6...)
Affinity DataKd:  0.0620nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621137(3,5-difluoro-N-((3S,4S)-4- fluoropiperidin-3-yl)-6...)
Affinity DataKd:  0.400nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621137(3,5-difluoro-N-((3S,4S)-4- fluoropiperidin-3-yl)-6...)
Affinity DataKd:  0.910nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [D835V](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621137(3,5-difluoro-N-((3S,4S)-4- fluoropiperidin-3-yl)-6...)
Affinity DataKd:  0.0250nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [F691L](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621137(3,5-difluoro-N-((3S,4S)-4- fluoropiperidin-3-yl)-6...)
Affinity DataKd:  0.0710nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [K663Q](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621137(3,5-difluoro-N-((3S,4S)-4- fluoropiperidin-3-yl)-6...)
Affinity DataKd:  3.10nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621137(3,5-difluoro-N-((3S,4S)-4- fluoropiperidin-3-yl)-6...)
Affinity DataKd:  1.20nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [R834Q](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621137(3,5-difluoro-N-((3S,4S)-4- fluoropiperidin-3-yl)-6...)
Affinity DataKd:  1.5nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [572-603](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621137(3,5-difluoro-N-((3S,4S)-4- fluoropiperidin-3-yl)-6...)
Affinity DataKd:  3nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent